Tariffs, FDA Chaos, and BioSecure in Limbo: How CDMOs Should Operate Under Uncertainty

Gil Roth, President of the Pharma & Biopharma Outsourcing Association (PBOA), walked CDMO Live Europe delegates through the full matrix of US policy pressures bearing on contract manufacturers, from Section 232 tariffs and most favored nation pricing to FDA workforce collapse and a stalled BioSecure Act.

Read the full article here.